logo
Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
rus
русский
eng
english

Site search



Correspondence address
310 Mira Street, Stavropol, Russia, 355017

Tel
+7 8652 352524; +7 8652 353229.

Fax
+7 8652 352524.

E-mail
medvestnik@stgmu.ru

The role of pro-inflammatory neuropeptides in ulcerative colitis

[Original research] [Internal diseases]
Vladimir Pavlenko; Svetlana Alexandrova; Elizaveta Tsurova; Leila Amirkhanova;

The study included 40 patients with ulcerative colitis during the treatment with various drug combinations. Serum levels of neuropeptides were measured with ELISA assay. It was found that during the exacerbation of ulcerative colitis the substance P (SP) is increased in serum, while there is a decrease in neurotensin serum levels. SP serum levels were in direct correlation with the severity of the disease under discussion, and the NT serum levels demonstrated inverse correlation.

Drugs used in the treatment schemes for ulcerative colitis are able to modulate the serum levels of neuropeptides under consideration in patients with active ulcerative colitis.

Download

References:
1. Bakulin I. G., Stanke D. A., Belousova E. A., Mikhailova T. L. Activity Indices pose objective criteria for assessing the severity of ulcerative colitis. Experimental Clinical Gastroenterology. 2008;6:14-16.
2. Beloborodova E. I., Burkovskaya V. A., Markidonova A. A. et al. Assessment of the severity of ulcerative colitis. Siberian Medical Journal. 2012;3:136-138.
3. Khaliph I. L., Loranskaya I. D. Inflammatory bowel disease (Ulcerative colitis and Crohn’s disease): The clinical findings, diagnosis and treatment. M.: «Miklosh»; 2004. 88 p.
4. Galeeva Z. M. Modern aspects of treatment for ulcerative colitis in terms of evidence based medicine. Bulletin of modern clinical medicine. 2010;2(3):47-50.
5. Gastroenterology: national guidelines / ed. V. T. Ivashkina, T. L. Lapina. M.: «GEOTAR Media»; 2008. 704 p.
6. Nonspecific inflammatory bowel disease / ed. G. I. Vorobyev, I. L. Khalif. M.: «Miklosh»; 2008. 400 p.
7. Komarov F. I., Osadchuk A. M., Osadchuk M. A., Kvetnoy I. M. Ulcerative colitis. Moscow: «Medical Information Agency»; 2008. 256 p.
8. Brun P., Mastrotto C., Beggiao E. et al. Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation. J. Am. Physiol. Gastrointest. Liver Physiol. 2005;288:621-629.
9. Neunlist М. et al. Changes in chemical coding of mysenteric neurones in ulcerative colitis. Gut. 2003;52:84-90.
10. Fiebich B. L., Schleicher S. et al. The neuropeptide substance P activates p38 mitogenactivated protein kinase resulting in IL-6 expression independently from NF-kappa B. J. Immunol. 2000;165:5606-5611.
11. Gandhu M. V. Visceral pain perception is determined by the duration of colitis and associated neuropeptide expression in mice. Gut. 2007;56:358-364.
12. Kara J., Gross M. D., Charalabos Pothoulakis M. D. Role of Neuropeptides in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2007;13:918-932.
13. Karagiannides I. Induction of colitis causes inflammatory responses in fat depots: evidence for substance P pathways in human mesenteric preadipocytes. Proc. Natl. Acad. Sci. USA. 2006;103:5207-5212.
14. Koon H. W., Pothoulakis C. Immunomodulatory Properties of Substance P. The Gastrointestinal System as a Model. N.Y. Ann. Acad. Sci. 2006;1088:23-40.
15. Riddell R. H., Kirsner J. B. Pathology of idiopathic inflammatory bowel disease. Inflammatory Bowel Disease. W.B. Saunders company, Philadelphia; 2000. P. 427-450.
16. Ter Beek W. P., Biemond I. et al. Substance P receptor expression in patients with inflammatory bowel disease. Determination by three different techniques, storage phosphor autoradiography, RT-PCR and immunohistochemistry. Neuropeptides. 2007;41:301- 306.
17. Hansen M. B. The Enteric Nervous System III: F Target for Pharmacological Treatment. Pharmacology & Toxicology. 2003;93:1-13.
18. Wehkamp J., Fellermann K., Herrlinger K. R. et al. Mechanisms of disease: defensins in gastrointestinal diseases. Nat. Clin. Pract. Gastroenterol. Hepatol. 2005;2:406-415.

Keywords: ulcerative colitis, neuropeptides


Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy